JAZZJazz Pharmaceuticals plc

$12B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4.3B+4.9% YoY

Gross Profit

$3.8B88.2% margin

Operating Income

$224M5.3% margin

Net Income

-$356M-8.3% margin

EPS (Diluted)

$-5.84

Cash Flow

Operating Cash Flow

$1.4B

Free Cash Flow

$1.3B

Stock-Based Comp.

$291M

Balance Sheet

Total Assets

$11.7B

Total Liabilities

$7.3B

Stockholders' Equity

$4.3B

Cash & Equivalents

$1.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.3B	$4.1B	+4.9%
Gross Profit	$3.8B	$3.6B	+3.9%
Operating Income	$224M	$717M	-68.7%
Net Income	-$356M	$560M	-163.6%

JAZZ FY 2025 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena